Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Microsoft and Meta's strong earnings reports eased investor fears of an economic slowdown amid President Trump's tariffs.

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Life expectancy in any given country says a lot about how its society values, supports and nurtures its people.

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

A beach in the Australian state of South Australia has been closed due to a mysterious foam. Surfers have reported cold and ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

WeightWatchers announced Tuesday it has filed for bankruptcy in an effort to "bolster its financial position" and "better ...

Billboard has published its World Albums chart for the week ending on May 3! Stray Kids’ special album “合 (HOP)” held steady at No. 4 in its 19th consecutive week on the chart, while their ...

Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies ICON plc, (NASDAQ: ICLR) a world-leading clinical ...